<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00916149</url>
  </required_header>
  <id_info>
    <org_study_id>LMC111754</org_study_id>
    <nct_id>NCT00916149</nct_id>
  </id_info>
  <brief_title>Cognitive Effects of Treatment of Interictal Discharges</brief_title>
  <official_title>Cognitive Effects of Treatment of Interictal Discharges</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Young Investigator Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National EpiFellows Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if levetiracetam (for patients with focal seizures)
      or lamotrigine (for patients with generalized seizures) reduces the occurrence of interictal
      discharges. The study investigates the possible correlation between reduction of interictal
      discharges and improved cognitive performance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with seizures will be studied with electroencephalography (EEG) and offered
      medication for prevention of recurrent seizures. Those with focal seizures will be treated
      with levetiracetam, and those with generalized seizures will be treated with lamotrigine.
      Subjects will undergo repeated EEG with concurrent cognitive testing before and after
      initiation of treatment. The proposed study tests 3 hypotheses: 1. that treatment with
      levetiracetam will reduce focal interictal epileptiform activity, 2. that treatment with
      lamotrigine will reduce generalized interictal epileptiform activity, and 3. that the extent
      of interictal epileptiform activity is inversely associated with performance on
      neuropsychological batteries and computerized cognitive testing. Repeated
      cognitive/neuropsychological testing obtained at steady state of the study drug and again
      after approximately 2 months on the final dosage will serve to evaluate the timecourse of
      potential cognitive benefits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Focal Interictal Discharges (IEDs) Per Hour, Pre to Post Treatment</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>This descriptive analysis examined the change in interictal discharge rates pre to post-treatment with levetiracetam in subjects with epilepsy and with no treatment in healthy controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Trial 1 Learning Score</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in California Verbal Learning Test (CVLT) Trial 1 learning score (range 0-16; higher score indicates better memory)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Total Learning</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in California Verbal Learning Test (CVLT) Total Learning Score (the total learning score is summed across 5 learning trials, range 0-80). Higher scores indicate better memory. Scores on the CVLT reflect the number of words recalled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Short Delay</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in California Verbal Learning Test (CVLT) Short Delay Recall Score (the score ranges from 0-16, reflecting the number of words recalled)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Long Delay</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in California Verbal Learning Test (CVLT) Long Delay Recall score (the score ranges from 0-16, reflecting the number of words recalled)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: BVMT-R Learning</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Learning score (the score ranges from 0-6, reflecting the number of shapes recalled on the initial learning trial)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: BVMT-R Total Learning</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Total Learning score (the score is summed across 3 learning trials, score range 0-18, reflecting the total number of shapes recalled)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: BVMT-R Delayed Recall</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Delayed Recall score (the score ranges from 0-6, reflecting the number of shapes recalled after a 25 minute delay)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: QOLIE</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Quality of Life Inventory in Epilepsy-89 score (QOLIE; score ranges from 0-100; higher scores reflect better quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: LNS</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Letter-Number Sequencing score (LNS; score ranges from 0-21; higher scores indicate better performance). The score reflects the number of items that the subject can correctly recall and place in proper alphabetical and numerical sequence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Spatial Span</measure>
    <time_frame>1 and 11 Weeks</time_frame>
    <description>Change in Spatial Span score (score ranges from 0-32; higher scores indicate better performance). Scores indicate the number of spatial sequences correctly recalled, forwards and backwards.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Digit Span</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Digit Span score (score ranges from 0-30; higher scores indicate better performance). Scores indicate the number of digit sequences correctly recalled, forwards and backwards.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Fluency</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Verbal Fluency score (Score range: lowest score = 0, with no upper limit, reflecting total number of words generated. Higher scores indicate better performance.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Stroop</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Stroop score (The score is the time for completion in seconds; less time reflects better performance.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Design Fluency</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Design Fluency score (Score range: lowest score = 0; there is no upper limit. A higher score reflects more designs generated, hence better performance.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Trails Test</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Trails Test score (The score is the time for completion in seconds. A lower score reflects better performance.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Grooved Pegboard</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Grooved Pegboard Score (The score is the time for completion. A lower score reflects better performance.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Digit Symbol</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Digit Symbol Score (The score is the number of items completed. A higher score reflects better performance.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CPT Accuracy</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Continuous Performance Test Score - Accuracy (CPT; score ranges from 0-100% correct)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CPT Reaction Time (CPT RT)</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Continuous Performance Test Score - Reaction Time, measured in seconds (CPT RT; less time reflects better performance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Choice Accuracy</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Choice Accuracy Score (indicate if red or blue stimulus; accuracy 0-100%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Choice Reaction Time</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Choice Reaction Time Score, with reaction time measured in seconds (indicate if red or blue stimulus; lower reaction time suggests better performance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Working Memory Accuracy</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Verbal Working Memory Accuracy Score (range 0-100%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Working Memory Reaction Time</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Verbal Working Memory Reaction Time Score, with reaction time measured in seconds (indicates processing speed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Non-verbal Working Memory Accuracy</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Non-verbal Working Memory Accuracy Score (accuracy ranges from 0-100%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Non-verbal Working Memory Reaction Time</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Non-verbal Working Memory Reaction Time Score (indicates processing speed, with reaction time measured in seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Recognition Accuracy</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Verbal Recognition Accuracy Score (accuracy ranges from 0-100%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Recognition Reaction Time</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Verbal Recognition Reaction Time Score (indicates processing speed, with reaction time measured in seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Facial Recognition Accuracy</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Facial Recognition Accuracy Score (accuracy ranges from 0-100%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Facial Recognition Reaction Time</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Facial Recognition Reaction Time Score (indicates processing speed, with reaction time measured in seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: NDDIE</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Neurological Disorders Depression Inventory for Epilepsy (NDDIE) score (scores range from 0-24; higher scores indicate greater depressive symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Adverse Events Profile (AEP)</measure>
    <time_frame>1 and 11 weeks</time_frame>
    <description>Change in Adverse Events Profile score (scores range from 19-76; higher scores indicate greater side effects)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Levetiracetam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 individuals with epilepsy, 6 of whom experience infrequent focal epileptiform discharges and 6 of whom experience frequent focal discharges. These individuals will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamotrigine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 individuals with epilepsy, 6 of whom experience infrequent generalized discharges and 6 of whom experience frequent generalized discharges. These individuals will be treated with lamotrigine (LMT). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LMT on discharge frequency, discharge duration, and cognitive task performance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>15 healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levetiracetam</intervention_name>
    <description>The dosage of levetiracetam will begin at 500mg twice per day (bid) for the first 4 days, and increase by 500mg every 5 days thereafter until a goal of 1500mg bid is reached. The subject will then remain on levetiracetam at 1500mg bid for 8 weeks, until the conclusion of the study. Medication will be supplied in 500mg tablets, to be taken orally.</description>
    <arm_group_label>Levetiracetam</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
    <description>The drug will be supplied in 25, 100 and 150mg tablets, to be taken orally per the titration schedule below:
The regimen will begin at 25mg once per day for the first two weeks, and increase to 50mg once per day during weeks 3 and 4. In week 5, the subject will take 50mg twice per day (bid). The dosage will increase to 50mg in the morning and 100mg at night during week 6. During week 7 the subject will take 100mg bid. During week 8, the subject will take 100mg in the morning and 150mg at night. At week 9, the subject will reach the target dose of 150mg bid. The subject will then remain on lamotrigine at 150mg bid for 7 weeks, until the conclusion of the study.</description>
    <arm_group_label>Lamotrigine</arm_group_label>
    <other_name>Lamictal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  18-55 years of age

          -  Normal Intelligence Quotient (IQ ≥ 80) as estimated by the Wechsler Test of Adult
             Reading (WTAR)

          -  Able to give consent

          -  The subject's treating physician is planning to prescribe levetiracetam for focal or
             lamotrigine for generalized seizure prevention

          -  Either symptomatic or idiopathic seizures.

        Exclusion Criteria:

          -  Non-native English speaking and/or multilingual

          -  Frequent seizures, since seizures themselves impair cognitive function and present a
             confounding variable. Subjects may have no more than one seizure or one cluster of
             seizures per month, with a cluster of seizures including more than one seizure, but
             between which the patient returns to baseline. The cluster may occur over no more than
             two consecutive days in one month.

          -  Seizure(s) must not have occurred within 3 days of enrollment and testing.

          -  Those with focal seizures who have evidence of renal disease (creatinine clearance
             less than 80) will be excluded from participation, as levetiracetam is cleared by the
             kidney.

          -  Those with focal seizures who have neutrophil counts &lt;1000/microliter will be excluded
             from participation, as levetiracetam may lower white blood cell counts.

          -  Those with focal seizures and irritability or mood swings will not be eligible for
             participation, as levetiracetam may exacerbate these symptoms. This will be determined
             by self-report, information obtained from the referring physician and medical record.

          -  Those with generalized seizures who have moderate to severe liver dysfunction
             (Child-Pugh Grades B and C) will be excluded from participation, as lamotrigine is
             cleared by the liver and the proposed dosing may not be tolerable in this population.
             This will be determined by self-report, information obtained from the referring
             physician, a comprehensive metabolic panel (routinely obtained in new-onset seizures)
             and the medical record.

          -  Subjects who are pregnant will not be eligible to take part in the study, as
             levetiracetam and lamotrigine are classified as Pregnancy Category C drugs and may
             pose risk to the fetus. Women of childbearing potential will have a urine pregnancy
             test prior to participation in the study. The urine pregnancy test will be repeated at
             the final study visit. Subjects with epilepsy who are of childbearing potential must
             use acceptable methods of birth control during the study, to be continued until one
             month after discontinuation of the study drug. If a subject does become pregnant
             during this time period, she must notify the investigators.

          -  Women who are breastfeeding may not participate in this study. Levetiracetam and
             lamotrigine may pass into the breastmilk of nursing mothers, posing a risk to the
             baby.

          -  Hypersensitivity to lamotrigine, levetiracetam or any components of these products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel B Hoch, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Aarts JH, Binnie CD, Smit AM, Wilkins AJ. Selective cognitive impairment during focal and generalized epileptiform EEG activity. Brain. 1984 Mar;107 ( Pt 1):293-308.</citation>
    <PMID>6421454</PMID>
  </reference>
  <reference>
    <citation>Browne TR, Penry JK, Proter RJ, Dreifuss FE. Responsiveness before, during, and after spike-wave paroxysms. Neurology. 1974 Jul;24(7):659-65.</citation>
    <PMID>4858089</PMID>
  </reference>
  <reference>
    <citation>Dodrill CB, Wilkus RJ. Relationships between intelligence and electroencephalographic epileptiform activity in adult epileptics. Neurology. 1976 Jun;26(6 PT 1):525-31.</citation>
    <PMID>819859</PMID>
  </reference>
  <reference>
    <citation>Gallagher MJ, Eisenman LN, Brown KM, Erbayat-Altay E, Hecimovic H, Fessler AJ, Attarian HP, Gilliam FG. Levetiracetam reduces spike-wave density and duration during continuous EEG monitoring in patients with idiopathic generalized epilepsy. Epilepsia. 2004 Jan;45(1):90-1.</citation>
    <PMID>14692914</PMID>
  </reference>
  <reference>
    <citation>Goode DJ, Penry JK, Dreifuss FE. Effects of paroxysmal spike-wave on continuous visual-motor performance. Epilepsia. 1970 Sep;11(3):241-54.</citation>
    <PMID>5276416</PMID>
  </reference>
  <reference>
    <citation>Hermann BP, Seidenberg M, Schoenfeld J, Peterson J, Leveroni C, Wyler AR. Empirical techniques for determining the reliability, magnitude, and pattern of neuropsychological change after epilepsy surgery. Epilepsia. 1996 Oct;37(10):942-50.</citation>
    <PMID>8822692</PMID>
  </reference>
  <reference>
    <citation>HOVEY HB, KOOI KA. Transient disturbances of thought processes and epilepsy. AMA Arch Neurol Psychiatry. 1955 Sep;74(3):287-91.</citation>
    <PMID>13248285</PMID>
  </reference>
  <reference>
    <citation>Kasteleijn-Nolst Trenité DG, Riemersma JB, Binnie CD, Smit AM, Meinardi H. The influence of subclinical epileptiform EEG discharges on driving behaviour. Electroencephalogr Clin Neurophysiol. 1987 Aug;67(2):167-70.</citation>
    <PMID>2439294</PMID>
  </reference>
  <reference>
    <citation>KOOI KA, HOVEY HB. Alterations in mental function and paroxysmal cerebral activity. AMA Arch Neurol Psychiatry. 1957 Sep;78(3):264-71.</citation>
    <PMID>13457501</PMID>
  </reference>
  <reference>
    <citation>Lee S, Sziklas V, Andermann F, Farnham S, Risse G, Gustafson M, Gates J, Penovich P, Al-Asmi A, Dubeau F, Jones-Gotman M. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia. 2003 Mar;44(3):339-47.</citation>
    <PMID>12614389</PMID>
  </reference>
  <reference>
    <citation>Lutz MT, Helmstaedter C. EpiTrack: tracking cognitive side effects of medication on attention and executive functions in patients with epilepsy. Epilepsy Behav. 2005 Dec;7(4):708-14. Epub 2005 Nov 2.</citation>
    <PMID>16266826</PMID>
  </reference>
  <reference>
    <citation>Meador KJ, Loring DW, Vahle VJ, Ray PG, Werz MA, Fessler AJ, Ogrocki P, Schoenberg MR, Miller JM, Kustra RP. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology. 2005 Jun 28;64(12):2108-14.</citation>
    <PMID>15985582</PMID>
  </reference>
  <reference>
    <citation>The Psychological Corporation. Wechsler Test of Adult Reading. 2001, San Antonio, TX: Harcourt Assessment</citation>
  </reference>
  <reference>
    <citation>Schwab RS. Research Publications. Reaction time in petit mal epilepsy. Association for Research in Nervous and Mental Disease 1947; 26:339-341.</citation>
  </reference>
  <reference>
    <citation>Selldén U. Psychotechnical performance related to paroxysmal discharges in EEG. Clinical Electroencephalography 1971; 2:18-27.</citation>
  </reference>
  <reference>
    <citation>Shewmon DA, Erwin RJ. The effect of focal interictal spikes on perception and reaction time. I. General considerations. Electroencephalogr Clin Neurophysiol. 1988 Apr;69(4):319-37.</citation>
    <PMID>2450731</PMID>
  </reference>
  <reference>
    <citation>Shewmon DA, Erwin RJ. The effect of focal interictal spikes on perception and reaction time. II. Neuroanatomic specificity. Electroencephalogr Clin Neurophysiol. 1988 Apr;69(4):338-52.</citation>
    <PMID>2450732</PMID>
  </reference>
  <reference>
    <citation>Synder, P.J. Epilepsy. In Snyder, P.J. &amp; Nussbaum, P.D, Clinical neuropsychology: a pocket handbook for assessment. 1998, Washington DC: American Psychological Association.</citation>
  </reference>
  <reference>
    <citation>Stodieck S, Steinhoff BJ, Kolmsee S, van Rijckevorsel K. Effect of levetiracetam in patients with epilepsy and interictal epileptiform discharges. Seizure. 2001 Dec;10(8):583-7.</citation>
    <PMID>11792161</PMID>
  </reference>
  <reference>
    <citation>Stroup E, Langfitt J, Berg M, McDermott M, Pilcher W, Como P. Predicting verbal memory decline following anterior temporal lobectomy (ATL). Neurology. 2003 Apr 22;60(8):1266-73.</citation>
    <PMID>12707428</PMID>
  </reference>
  <reference>
    <citation>TIZARD B, MARGERISON JH. THE RELATIONSHIP BETWEEN GENERALIZED PAROXYSMAL E.E.G. DISCHARGES AND VARIOUS TEST SITUATIONS IN TWO EPILEPTIC PATIENTS. J Neurol Neurosurg Psychiatry. 1963 Aug;26:308-13.</citation>
    <PMID>14043044</PMID>
  </reference>
  <reference>
    <citation>Tizard B, Margerison JH. Psychological functions during wave-spike discharge. British Journal of Social and Clinical Psychology 1963b; 3:6-15.</citation>
  </reference>
  <reference>
    <citation>Tromp SC, Weber JW, Aldenkamp AP, Arends J, vander Linden I, Diepman L. Relative influence of epileptic seizures and of epilepsy syndrome on cognitive function. J Child Neurol. 2003 Jun;18(6):407-12.</citation>
    <PMID>12886976</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>June 5, 2009</study_first_submitted>
  <study_first_submitted_qc>June 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2009</study_first_posted>
  <results_first_submitted>March 22, 2017</results_first_submitted>
  <results_first_submitted_qc>July 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 7, 2018</results_first_posted>
  <last_update_submitted>September 5, 2018</last_update_submitted>
  <last_update_submitted_qc>September 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Beth Ami Leeman, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Cognition</keyword>
  <keyword>Lamictal</keyword>
  <keyword>Lamotrigine</keyword>
  <keyword>Keppra</keyword>
  <keyword>Levetiracetam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Levetiracetam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>5 subjects enrolled in the Lamotrigine arm. They underwent study procedures, including EEG. The study aim was to compare subjects with and without frequent discharges on EEG. None of these subjects had frequent discharges, and no additional subjects could be recruited. Hence, planned comparisons could not be made and the data were not analyzed.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>No Treatment</title>
          <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
        </group>
        <group group_id="P2">
          <title>Levetiracetam</title>
          <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
        </group>
        <group group_id="P3">
          <title>Lamotrigine</title>
          <description>Individuals with primary generalized epilepsy, who will be treated with lamotrigine (LMT). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LMT on discharge frequency, discharge duration, and cognitive task performance.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to place scalp EEG leads</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>16 controls enrolled in &quot;no treatment&quot;; 1 subject did not perform tests due to vision loss and difficulty placing EEG leads. Hence, there are 15 subjects in the &quot;no treatment&quot; arm.
We were unable to recruit any subjects with generalized epilepsy and frequent discharges, hence we did not complete the analysis of this arm as planned.</population>
      <group_list>
        <group group_id="B1">
          <title>No Treatment</title>
          <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
        </group>
        <group group_id="B2">
          <title>Levetiracetam</title>
          <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
        </group>
        <group group_id="B3">
          <title>Lamotrigine</title>
          <description>Individuals with primary generalized epilepsy, who will be treated with lamotrigine (LMT). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LMT on discharge frequency, discharge duration, and cognitive task performance.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.4" lower_limit="18" upper_limit="43"/>
                    <measurement group_id="B2" value="35.8" lower_limit="22" upper_limit="50"/>
                    <measurement group_id="B3" value="31.4" lower_limit="18" upper_limit="43"/>
                    <measurement group_id="B4" value="35.3" lower_limit="18" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Focal Interictal Discharges (IEDs) Per Hour, Pre to Post Treatment</title>
        <description>This descriptive analysis examined the change in interictal discharge rates pre to post-treatment with levetiracetam in subjects with epilepsy and with no treatment in healthy controls.</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>In a preliminary analysis, data from 11 healthy controls and 6 subjects with partial-onset epilepsy were evaluated.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Focal Interictal Discharges (IEDs) Per Hour, Pre to Post Treatment</title>
          <description>This descriptive analysis examined the change in interictal discharge rates pre to post-treatment with levetiracetam in subjects with epilepsy and with no treatment in healthy controls.</description>
          <population>In a preliminary analysis, data from 11 healthy controls and 6 subjects with partial-onset epilepsy were evaluated.</population>
          <units>IEDs/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.8" spread="71.8"/>
                    <measurement group_id="O2" value=".54" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in frequency of IEDs/per hour was assessed for each group (levetiracetam and no treatment)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>For each group (levetiracetam and no treatment), the change in IEDs/hour from pre to post-intervention: p &gt;0.05. The a priori threshold for statistical significance was p=0.05.</p_value_desc>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Trial 1 Learning Score</title>
        <description>Change in California Verbal Learning Test (CVLT) Trial 1 learning score (range 0-16; higher score indicates better memory)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Trial 1 Learning Score</title>
          <description>Change in California Verbal Learning Test (CVLT) Trial 1 learning score (range 0-16; higher score indicates better memory)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across measures.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" spread="1.29"/>
                    <measurement group_id="O2" value="2.5" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the CVLT Trial 1 Learning Score from pre to post time points in the no treatment group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the CVLT Trial 1 Learning Score from pre to post time points in the levetiracetam group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Total Learning</title>
        <description>Change in California Verbal Learning Test (CVLT) Total Learning Score (the total learning score is summed across 5 learning trials, range 0-80). Higher scores indicate better memory. Scores on the CVLT reflect the number of words recalled.</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Total Learning</title>
          <description>Change in California Verbal Learning Test (CVLT) Total Learning Score (the total learning score is summed across 5 learning trials, range 0-80). Higher scores indicate better memory. Scores on the CVLT reflect the number of words recalled.</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>number recalled</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.09" spread="8.79"/>
                    <measurement group_id="O2" value="5.5" spread="6.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the CVLT Total Learning Score from pre to post time points in the no treatment group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the CVLT Total Learning Score from pre to post time points in the levetiracetam treatment group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Short Delay</title>
        <description>Change in California Verbal Learning Test (CVLT) Short Delay Recall Score (the score ranges from 0-16, reflecting the number of words recalled)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Short Delay</title>
          <description>Change in California Verbal Learning Test (CVLT) Short Delay Recall Score (the score ranges from 0-16, reflecting the number of words recalled)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>number recalled</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="2.65"/>
                    <measurement group_id="O2" value="-0.4" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the CVLT Short Delay score from pre to post time points in the no treatment group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the CVLT Short Delay score from pre to post time points in the levetiracetam treatment group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Long Delay</title>
        <description>Change in California Verbal Learning Test (CVLT) Long Delay Recall score (the score ranges from 0-16, reflecting the number of words recalled)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Long Delay</title>
          <description>Change in California Verbal Learning Test (CVLT) Long Delay Recall score (the score ranges from 0-16, reflecting the number of words recalled)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>number recalled</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="3.21"/>
                    <measurement group_id="O2" value="2.67" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the CVLT Long Delay score from pre to post time points in the no treatment group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the CVLT Long Delay score from pre to post time points in the levetiracetam treatment group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.045</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: BVMT-R Learning</title>
        <description>Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Learning score (the score ranges from 0-6, reflecting the number of shapes recalled on the initial learning trial)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: BVMT-R Learning</title>
          <description>Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Learning score (the score ranges from 0-6, reflecting the number of shapes recalled on the initial learning trial)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>number recalled</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".45" spread="1.92"/>
                    <measurement group_id="O2" value=".33" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the BVMT-R Learning score from pre to post time points in the no treatment group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the BVMT-R Learning score from pre to post time points in the levetiracetam treatment group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: BVMT-R Total Learning</title>
        <description>Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Total Learning score (the score is summed across 3 learning trials, score range 0-18, reflecting the total number of shapes recalled)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: BVMT-R Total Learning</title>
          <description>Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Total Learning score (the score is summed across 3 learning trials, score range 0-18, reflecting the total number of shapes recalled)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>number recalled</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="3.05"/>
                    <measurement group_id="O2" value=".17" spread="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the BVMT-R Total Learning score from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the BVMT-R Total Learning score from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: BVMT-R Delayed Recall</title>
        <description>Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Delayed Recall score (the score ranges from 0-6, reflecting the number of shapes recalled after a 25 minute delay)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: BVMT-R Delayed Recall</title>
          <description>Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Delayed Recall score (the score ranges from 0-6, reflecting the number of shapes recalled after a 25 minute delay)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>number recalled</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".36" spread=".81"/>
                    <measurement group_id="O2" value=".33" spread=".52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the BVMT-R Delayed Recall score from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the BVMT-R Delayed Recall score from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: QOLIE</title>
        <description>Change in Quality of Life Inventory in Epilepsy-89 score (QOLIE; score ranges from 0-100; higher scores reflect better quality of life)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures. The QOLIE is specific to epilepsy and was only administered in that subject group.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: QOLIE</title>
          <description>Change in Quality of Life Inventory in Epilepsy-89 score (QOLIE; score ranges from 0-100; higher scores reflect better quality of life)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures. The QOLIE is specific to epilepsy and was only administered in that subject group.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="19.6" spread="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the QOLIE score from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: LNS</title>
        <description>Change in Letter-Number Sequencing score (LNS; score ranges from 0-21; higher scores indicate better performance). The score reflects the number of items that the subject can correctly recall and place in proper alphabetical and numerical sequence.</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: LNS</title>
          <description>Change in Letter-Number Sequencing score (LNS; score ranges from 0-21; higher scores indicate better performance). The score reflects the number of items that the subject can correctly recall and place in proper alphabetical and numerical sequence.</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".18" spread="1.66"/>
                    <measurement group_id="O2" value="-0.5" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Letter Number Sequencing score from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Letter Number Sequencing score from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Spatial Span</title>
        <description>Change in Spatial Span score (score ranges from 0-32; higher scores indicate better performance). Scores indicate the number of spatial sequences correctly recalled, forwards and backwards.</description>
        <time_frame>1 and 11 Weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Spatial Span</title>
          <description>Change in Spatial Span score (score ranges from 0-32; higher scores indicate better performance). Scores indicate the number of spatial sequences correctly recalled, forwards and backwards.</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>number recalled</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".36" spread="3.08"/>
                    <measurement group_id="O2" value="-1.67" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Spatial Span score from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Spatial Span score from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Digit Span</title>
        <description>Change in Digit Span score (score ranges from 0-30; higher scores indicate better performance). Scores indicate the number of digit sequences correctly recalled, forwards and backwards.</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Digit Span</title>
          <description>Change in Digit Span score (score ranges from 0-30; higher scores indicate better performance). Scores indicate the number of digit sequences correctly recalled, forwards and backwards.</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>number recalled</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".73" spread="4"/>
                    <measurement group_id="O2" value="-.33" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Digit Span score from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Digit Span score from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Fluency</title>
        <description>Change in Verbal Fluency score (Score range: lowest score = 0, with no upper limit, reflecting total number of words generated. Higher scores indicate better performance.)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Fluency</title>
          <description>Change in Verbal Fluency score (Score range: lowest score = 0, with no upper limit, reflecting total number of words generated. Higher scores indicate better performance.)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" spread="11.26"/>
                    <measurement group_id="O2" value="-.83" spread="12.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Verbal Fluency score from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Verbal Fluency score from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Stroop</title>
        <description>Change in Stroop score (The score is the time for completion in seconds; less time reflects better performance.)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Stroop</title>
          <description>Change in Stroop score (The score is the time for completion in seconds; less time reflects better performance.)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".98" spread="12.15"/>
                    <measurement group_id="O2" value="-7.3" spread="14.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in Stroop performance from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in Stroop performance from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Design Fluency</title>
        <description>Change in Design Fluency score (Score range: lowest score = 0; there is no upper limit. A higher score reflects more designs generated, hence better performance.)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Design Fluency</title>
          <description>Change in Design Fluency score (Score range: lowest score = 0; there is no upper limit. A higher score reflects more designs generated, hence better performance.)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="4.52"/>
                    <measurement group_id="O2" value=".83" spread="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Design Fluency score from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Design Fluency score from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Trails Test</title>
        <description>Change in Trails Test score (The score is the time for completion in seconds. A lower score reflects better performance.)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Trails Test</title>
          <description>Change in Trails Test score (The score is the time for completion in seconds. A lower score reflects better performance.)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.51" spread="18.73"/>
                    <measurement group_id="O2" value="11.29" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in performance on the Trails Test from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in performance on the Trails Test from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Grooved Pegboard</title>
        <description>Change in Grooved Pegboard Score (The score is the time for completion. A lower score reflects better performance.)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Grooved Pegboard</title>
          <description>Change in Grooved Pegboard Score (The score is the time for completion. A lower score reflects better performance.)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.73" spread="18.9"/>
                    <measurement group_id="O2" value="-4.36" spread="23.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in performance on the Grooved Pegboard task from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in performance on the Grooved Pegboard task from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Digit Symbol</title>
        <description>Change in Digit Symbol Score (The score is the number of items completed. A higher score reflects better performance.)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Digit Symbol</title>
          <description>Change in Digit Symbol Score (The score is the number of items completed. A higher score reflects better performance.)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="2.78"/>
                    <measurement group_id="O2" value="1.5" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Digit Symbol score from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Digit Symbol score from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CPT Accuracy</title>
        <description>Change in Continuous Performance Test Score - Accuracy (CPT; score ranges from 0-100% correct)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CPT Accuracy</title>
          <description>Change in Continuous Performance Test Score - Accuracy (CPT; score ranges from 0-100% correct)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>percentage of correct responses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.03"/>
                    <measurement group_id="O2" value=".01" spread=".03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the CPT Accuracy score from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the CPT Accuracy score from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CPT Reaction Time (CPT RT)</title>
        <description>Change in Continuous Performance Test Score - Reaction Time, measured in seconds (CPT RT; less time reflects better performance)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CPT Reaction Time (CPT RT)</title>
          <description>Change in Continuous Performance Test Score - Reaction Time, measured in seconds (CPT RT; less time reflects better performance)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="110.54"/>
                    <measurement group_id="O2" value="-11.33" spread="52.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the CPT reaction time from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the CPT reaction time from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Choice Accuracy</title>
        <description>Change in Choice Accuracy Score (indicate if red or blue stimulus; accuracy 0-100%)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Choice Accuracy</title>
          <description>Change in Choice Accuracy Score (indicate if red or blue stimulus; accuracy 0-100%)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>percentage of correct responses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".02" spread=".01"/>
                    <measurement group_id="O2" value=".1" spread="NA">one one data point obtained, hence no standard deviation can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Choice Accuracy score from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Choice Reaction Time</title>
        <description>Change in Choice Reaction Time Score, with reaction time measured in seconds (indicate if red or blue stimulus; lower reaction time suggests better performance)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Choice Reaction Time</title>
          <description>Change in Choice Reaction Time Score, with reaction time measured in seconds (indicate if red or blue stimulus; lower reaction time suggests better performance)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.96" spread="51.16"/>
                    <measurement group_id="O2" value=".45" spread="95.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Choice Reaction Time score from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Working Memory Accuracy</title>
        <description>Change in Verbal Working Memory Accuracy Score (range 0-100%)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Working Memory Accuracy</title>
          <description>Change in Verbal Working Memory Accuracy Score (range 0-100%)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>percentage of correct responses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread=".02"/>
                    <measurement group_id="O2" value="-.02" spread=".02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Verbal Working Memory Accuracy score from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Verbal Working Memory Accuracy score from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Working Memory Reaction Time</title>
        <description>Change in Verbal Working Memory Reaction Time Score, with reaction time measured in seconds (indicates processing speed)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Working Memory Reaction Time</title>
          <description>Change in Verbal Working Memory Reaction Time Score, with reaction time measured in seconds (indicates processing speed)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.76" spread="112.04"/>
                    <measurement group_id="O2" value="-9.36" spread="155.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Verbal Working Memory Reaction Time from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Verbal Working Memory Reaction Time from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Non-verbal Working Memory Accuracy</title>
        <description>Change in Non-verbal Working Memory Accuracy Score (accuracy ranges from 0-100%)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Non-verbal Working Memory Accuracy</title>
          <description>Change in Non-verbal Working Memory Accuracy Score (accuracy ranges from 0-100%)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>percentage of correct responses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.01" spread=".03"/>
                    <measurement group_id="O2" value="0" spread=".02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Non-verbal Working Memory Accuracy score from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Non-verbal Working Memory Accuracy score from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Non-verbal Working Memory Reaction Time</title>
        <description>Change in Non-verbal Working Memory Reaction Time Score (indicates processing speed, with reaction time measured in seconds)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Non-verbal Working Memory Reaction Time</title>
          <description>Change in Non-verbal Working Memory Reaction Time Score (indicates processing speed, with reaction time measured in seconds)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.99" spread="85.18"/>
                    <measurement group_id="O2" value="-25.54" spread="131.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Non-verbal Working Memory Reaction Time from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Non-verbal Working Memory Reaction Time from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Recognition Accuracy</title>
        <description>Change in Verbal Recognition Accuracy Score (accuracy ranges from 0-100%)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Recognition Accuracy</title>
          <description>Change in Verbal Recognition Accuracy Score (accuracy ranges from 0-100%)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>percentage of correct responses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".02" spread=".11"/>
                    <measurement group_id="O2" value=".14" spread=".27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Verbal Recognition Accuracy score from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Verbal Recognition Accuracy score from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Recognition Reaction Time</title>
        <description>Change in Verbal Recognition Reaction Time Score (indicates processing speed, with reaction time measured in seconds)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Recognition Reaction Time</title>
          <description>Change in Verbal Recognition Reaction Time Score (indicates processing speed, with reaction time measured in seconds)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" spread="93.5"/>
                    <measurement group_id="O2" value="-6.1" spread="98.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Verbal Recognition Reaction Time from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Verbal Recognition Reaction Time from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Facial Recognition Accuracy</title>
        <description>Change in Facial Recognition Accuracy Score (accuracy ranges from 0-100%)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Facial Recognition Accuracy</title>
          <description>Change in Facial Recognition Accuracy Score (accuracy ranges from 0-100%)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>percentage of correct responses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".01" spread=".17"/>
                    <measurement group_id="O2" value=".03" spread=".06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Facial Recognition Accuracy score from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Facial Recognition Accuracy score from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Facial Recognition Reaction Time</title>
        <description>Change in Facial Recognition Reaction Time Score (indicates processing speed, with reaction time measured in seconds)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Facial Recognition Reaction Time</title>
          <description>Change in Facial Recognition Reaction Time Score (indicates processing speed, with reaction time measured in seconds)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.76" spread="168.66"/>
                    <measurement group_id="O2" value=".61" spread="50.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Facial Recognition Reaction Time from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the Facial Recognition Reaction Time from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: NDDIE</title>
        <description>Change in Neurological Disorders Depression Inventory for Epilepsy (NDDIE) score (scores range from 0-24; higher scores indicate greater depressive symptoms)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: NDDIE</title>
          <description>Change in Neurological Disorders Depression Inventory for Epilepsy (NDDIE) score (scores range from 0-24; higher scores indicate greater depressive symptoms)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="2.52"/>
                    <measurement group_id="O2" value="1.5" spread="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the NDDIE score from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the NDDIE score from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Adverse Events Profile (AEP)</title>
        <description>Change in Adverse Events Profile score (scores range from 19-76; higher scores indicate greater side effects)</description>
        <time_frame>1 and 11 weeks</time_frame>
        <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam</title>
            <description>Individuals with epilepsy who will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Adverse Events Profile (AEP)</title>
          <description>Change in Adverse Events Profile score (scores range from 19-76; higher scores indicate greater side effects)</description>
          <population>Not all subjects completed each neuropsychological test (e.g., lack of time, fatigue, computer issues); hence, the number analyzed may differ across outcome measures.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" spread="6.75"/>
                    <measurement group_id="O2" value="1" spread="9.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the AEP score from pre to post time points in the no treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis assessed the change in the AEP score from pre to post time points in the levetiracetam treatment group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Wilcoxon Signed Ranks Test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Levetiracetam</title>
          <description>8 individuals with focal-onset epilepsy. These individuals 12will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.</description>
        </group>
        <group group_id="E2">
          <title>Lamotrigine</title>
          <description>5 individuals with generalized epilepsy. These individuals will be treated with lamotrigine (LMT). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LMT on discharge frequency, discharge duration, and cognitive task performance.</description>
        </group>
        <group group_id="E3">
          <title>No Treatment</title>
          <description>12 healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Frustration during cognitive testing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Beth Leeman-Markowski, MD</name_or_title>
      <organization>VA New York Harbor Healthcare System, NYU</organization>
      <phone>212-686-7500</phone>
      <email>beth.leeman-markowski@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

